Exelixis Stock Forecast, Price & News

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

Is Exelixis a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Exelixis stock.
View analyst ratings for Exelixis or view top-rated stocks.

How has Exelixis' stock price been impacted by COVID-19?

Exelixis' stock was trading at $17.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EXEL stock has decreased by 2.8% and is now trading at $16.84.
View which stocks have been most impacted by COVID-19.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Exelixis.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported $0.12 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.19 by $0.07. Exelixis had a trailing twelve-month return on equity of 8.27% and a net margin of 13.10%. During the same quarter last year, the business posted ($0.10) EPS.
View Exelixis' earnings history.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.35 billion, compared to the consensus revenue estimate of $1.39 billion.

What price target have analysts set for EXEL?

11 analysts have issued twelve-month price targets for Exelixis' shares. Their forecasts range from $26.00 to $52.00. On average, they anticipate Exelixis' share price to reach $33.10 in the next year. This suggests a possible upside of 96.6% from the stock's current price.
View analysts' price targets for Exelixis or view top-rated stocks among Wall Street analysts.

Who are Exelixis' key executives?

Exelixis' management team includes the following people:

• Michael M. Morrissey, President, Chief Executive Officer & Director
• Dana T. Aftab, Executive Vice President-Business Operations
• Christopher J. Senner, Chief Financial Officer & Executive Vice President
• Peter Lamb, Chief Scientific Officer & EVP-Scientific Strategy (LinkedIn Profile)
• Jeffrey J. Hessekiel, Executive Vice President & General Counsel (LinkedIn Profile)

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among Exelixis' employees.

Who are some of Exelixis' key competitors?

Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Incyte (INCY), Repligen (RGEN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Halozyme Therapeutics (HALO).
View all of EXEL's competitors.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.08%), Renaissance Technologies LLC (5.55%), Farallon Capital Management LLC (3.05%), Polar Capital Holdings Plc (1.29%), Geode Capital Management LLC (1.27%) and Stephens Investment Management Group LLC (1.09%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends for Exelixis.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Farallon Capital Management LLC, Balyasny Asset Management LLC, Balyasny Asset Management LLC, American Century Companies Inc., Renaissance Technologies LLC, Assenagon Asset Management S.A., and Sargent Investment Group LLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Patrick J Haley, Peter Lamb, Stelios Papadopoulos, and Vincent T Marchesi.
View insider buying and selling activity for Exelixis or view top insider-selling stocks.

Which institutional investors are buying Exelixis stock?

EXEL stock was bought by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Janus Henderson Group PLC, Polar Capital Holdings Plc, Krensavage Asset Management LLC, Two Sigma Advisers LP, Allianz Asset Management GmbH, Dimensional Fund Advisors LP, and Marshall Wace LLP.
View insider buying and selling activity for Exelixis or or view top insider-buying stocks.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $16.84.

How much money does Exelixis make?

Exelixis has a market capitalization of $5.33 billion and generates $987.54 million in revenue each year. The biotechnology company earns $111.78 million in net income (profit) each year or $0.51 on an earnings per share basis.

How many employees does Exelixis have?

Exelixis employs 773 workers across the globe.

When was Exelixis founded?

Exelixis was founded in 1994.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

Where are Exelixis' headquarters?

Exelixis is headquartered at 1851 Harbor Bay Parkway, Alameda CA, 94502.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at (650) 837-7000, via email at [email protected], or via fax at 650-837-8300.